Navigation Links
Experimental drug reverses key cognitive deficits, pathology in Alzheimer's

A new drug that enhances the activity of a key brain cell receptor involved in Alzheimer's disease (AD) reverses learning and memory deficits in mice engineered to have pathological hallmarks of the disease. What's more, the drug, called AF267B, reduces both of the pathologies--the brain-clogging buildup of protein "amyloid plaque" outside brain cells and the protein "neurofibrillary tangles" inside the cells.

In an article in the March 2, 2006, issue of Neuron, Dr. Frank LaFerla of the University of California, Irvine and his colleagues reported the first in vivo studies of the drug's effects. AF267B was developed by coauthor Abraham Fisher to activate particular receptors for the neurotransmitter acetylcholine. These specific receptors, called M1 receptors, are abundant in areas of the brain--the cortex and hippocampus--known to develop severe deposits of plaques and tangles in AD patients. Dysfunction in acetylcholine receptors has been shown to be characteristic of early stages of AD.

Receptors are proteins on the neuronal surface that are triggered by the chemical signals called neurotransmitters. This triggering initiates such cellular responses as the wave of electrical excitation of a nerve impulse.

As an animal model of AD, the researchers used a "triple knockout" mouse in which three key genes involved in normal brain protein processing pathways had been knocked out, creating both amyloid plaques and neurofibrillary tangles.

In their experiments, the researchers gave the knockout mice eight weeks of daily doses of AF267B and tested the animals' learning and memory abilities. One test involved measuring how well the treated animals could learn to find a submerged platform in a tank of murky water. This test is known to depend on the function of the hippocampus. The researchers found that the treated mice performed significantly better than untreated knockout mice on the task.

Significantly, found the researchers, the poorer performance of the untreated mice resulted from their relative inability to remember from day-to-day the location of the platform.

In another memory test, however, the treated mice did not show improved performance compared to untreated mice. In this test--which depends on the function of another Alzheimer's-affected brain region called the amygdala--the mice were required to learn to associate a dark chamber with an unpleasant shock.

Analyzing the brain tissue of the untreated and treated mice, the researchers found that treatment with AF267B reduced levels of both pathological plaques and tangles in the cortex and hippocampus, but not in the amygdala.

In experiments that demonstrated the central role of M1 receptors in AD-like pathology, the researchers also tested the effects on the mice of another drug, dicyclomine, that blocks M1 receptors. They found that both normal and knockout mice treated with the drug showed the characteristic learning and memory impairments, as well as amyloid and tangle pathologies.

The researchers also studied the effects of AF267B treatment on key enzymes involved in amyloid protein processing in the cell. They found evidence that the drug appears to work by affecting levels of these enzymes, as a result of its enhancement of M1 receptor activity.

The researchers concluded that "the results of the present study show the remarkable therapeutic potential of AF267B in attenuating the major hallmark neuropathological lesions relevant to AD and in restoring cognitive function, at least for certain tasks." They also pointed out the importance of the finding that administering dicyclomine to block M1 receptors exacerbated the disease pathologies.

"Further work, including clinical trials in humans, will be necessary to determine if this new generation of M1 agonists will produce a similar therapeutic efficacy as was observed in the [knockout] mice," they concluded.


'"/>

Source:Cell Press


Related biology news :

1. NIAID Initiates Trial of Experimental Avian Flu Vaccine
2. Experimental shingles vaccine proves effective in nationwide study
3. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
4. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
5. Experimental RNA-based drug kills prostate cancer cells effectively and safely
6. Experimental vaccine protects lab animals against several strains of H5N1
7. Experimental vaccine protects mice against deadly 1918 flu virus
8. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
9. Experimental vaccine given during pregnancy reduces stillbirths from common virus
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. Genetic therapy reverses nervous system damage in animal model of inherited human disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, ... webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured ... event is free and open to the public, but registration is required. , ...
Breaking Biology Technology: